NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Instylla

Instylla

Private
Bedford, MassachusettsHealthcare & Life Scienceshttps://instylla.com/

Last Round

Early Stage

VC

Jul 28, 2026

Est. Valuation

$125.43M

Total Funding Raised

$81.96M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Instylla is a medical device company that develops liquid embolic solutions for interventional radiology, aimed at providing controlled and effective embolization to enhance patient outcomes.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

interventional oncologytumor embolizationhydrogel embolicinterventional radiologymedical deviceminimally invasive surgeryembolic agenthypervascular tumorbioresorbable deviceIRembolicstumor blockagevascular occlusion

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Instylla Comparables

Compare Instylla with similar companies based on industry and business-model similarity.

Instylla comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Fluidx Medical Technology
84%
ABK Biomedical
81%
Cortex, Inc.
79%

Instylla Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early Stage VCJul 28, 2026
Series CAug 1, 2023
Series BOct 13, 2020
DebtApr 28, 2020
Series A ExtensionJun 12, 2018
Series A
Jun 6, 2017

Instylla Investors

Notable investors and investment history

Instylla investors
InvestorRounds
Incept LLCSeries C, Series A, Series B
Ascension VenturesSeries C, Series A, Series B
CHVSeries C, Series B
Incept AISeries C, Series B
Sparta Group LLCSeries C, Series B
Catalyst Health VenturesSeries C, Series A, Series B
Excelestar VenturesSeries C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    Embrace(TM) Hydrogel Embolic System approved for tumor embolization.

  • Jan 1, 2026

    Embrace(TM) Hydrogel Embolic System approved for tumor embolization.

Instylla Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Instylla Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Instylla's valuation, stock price, and market status.

Firmographic Details

HeadquartersBedford, Massachusetts
Employee Range73
Year Founded2017
Last FundingJul 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.